Cancer gene therapy

Hard lessons and new courses

Research output: Contribution to journalArticle

184 Citations (Scopus)

Abstract

Gene therapy for the treatment of cancer was initiated with high levels of optimism and enthusiasm. Recently, this perception has had to be tempered by the realisation that efficiency and accuracy of gene delivery remain the most significant barriers to its success. So far, there has been a disappointing inability to reach target cells with sufficient efficacy to generate high enough levels of direct killing and this has necessitated the invocation of bystander effects in order for any potential strategy to be convincing. At least in the foreseeable future, clinical advance will come from cooperation with other more established disciplines - such as chemotherapy, radiotherapy and immunotherapy. This is inevitable - and necessary - in order to prove that gene therapy can have efficacy as part of a combinatorial therapy, before hoping to move clinical mountains alone. In addition, there will have to be a thorough understanding of the clinical situations in which gene therapy will be used in order both to understand its own limitations, and to exploit its full potential. This will enable it to find the appropriate clinical niche in which its abilities will be optimally useful. Finally, anyone wishing to practise clinical cancer gene therapy will rapidly have to learn the ways of the free market and be able to juggle commercial necessities with ideological purity.

Original languageEnglish (US)
Pages (from-to)2-8
Number of pages7
JournalGene Therapy
Volume7
Issue number1
StatePublished - Jan 2000

Fingerprint

Neoplasm Genes
Genetic Therapy
Bystander Effect
Aptitude
Immunotherapy
Radiotherapy
Efficiency
Drug Therapy
Therapeutics
Genes
Neoplasms

Keywords

  • Cancer
  • Gene therapy immunotherapy
  • Targeting
  • Viral vector

ASJC Scopus subject areas

  • Genetics

Cite this

Cancer gene therapy : Hard lessons and new courses. / Vile, Richard Geoffrey; Russell, Stephen J; Lemoine, N. R.

In: Gene Therapy, Vol. 7, No. 1, 01.2000, p. 2-8.

Research output: Contribution to journalArticle

@article{f56b6f0f3b884473a62f422499cc63bf,
title = "Cancer gene therapy: Hard lessons and new courses",
abstract = "Gene therapy for the treatment of cancer was initiated with high levels of optimism and enthusiasm. Recently, this perception has had to be tempered by the realisation that efficiency and accuracy of gene delivery remain the most significant barriers to its success. So far, there has been a disappointing inability to reach target cells with sufficient efficacy to generate high enough levels of direct killing and this has necessitated the invocation of bystander effects in order for any potential strategy to be convincing. At least in the foreseeable future, clinical advance will come from cooperation with other more established disciplines - such as chemotherapy, radiotherapy and immunotherapy. This is inevitable - and necessary - in order to prove that gene therapy can have efficacy as part of a combinatorial therapy, before hoping to move clinical mountains alone. In addition, there will have to be a thorough understanding of the clinical situations in which gene therapy will be used in order both to understand its own limitations, and to exploit its full potential. This will enable it to find the appropriate clinical niche in which its abilities will be optimally useful. Finally, anyone wishing to practise clinical cancer gene therapy will rapidly have to learn the ways of the free market and be able to juggle commercial necessities with ideological purity.",
keywords = "Cancer, Gene therapy immunotherapy, Targeting, Viral vector",
author = "Vile, {Richard Geoffrey} and Russell, {Stephen J} and Lemoine, {N. R.}",
year = "2000",
month = "1",
language = "English (US)",
volume = "7",
pages = "2--8",
journal = "Gene Therapy",
issn = "0969-7128",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Cancer gene therapy

T2 - Hard lessons and new courses

AU - Vile, Richard Geoffrey

AU - Russell, Stephen J

AU - Lemoine, N. R.

PY - 2000/1

Y1 - 2000/1

N2 - Gene therapy for the treatment of cancer was initiated with high levels of optimism and enthusiasm. Recently, this perception has had to be tempered by the realisation that efficiency and accuracy of gene delivery remain the most significant barriers to its success. So far, there has been a disappointing inability to reach target cells with sufficient efficacy to generate high enough levels of direct killing and this has necessitated the invocation of bystander effects in order for any potential strategy to be convincing. At least in the foreseeable future, clinical advance will come from cooperation with other more established disciplines - such as chemotherapy, radiotherapy and immunotherapy. This is inevitable - and necessary - in order to prove that gene therapy can have efficacy as part of a combinatorial therapy, before hoping to move clinical mountains alone. In addition, there will have to be a thorough understanding of the clinical situations in which gene therapy will be used in order both to understand its own limitations, and to exploit its full potential. This will enable it to find the appropriate clinical niche in which its abilities will be optimally useful. Finally, anyone wishing to practise clinical cancer gene therapy will rapidly have to learn the ways of the free market and be able to juggle commercial necessities with ideological purity.

AB - Gene therapy for the treatment of cancer was initiated with high levels of optimism and enthusiasm. Recently, this perception has had to be tempered by the realisation that efficiency and accuracy of gene delivery remain the most significant barriers to its success. So far, there has been a disappointing inability to reach target cells with sufficient efficacy to generate high enough levels of direct killing and this has necessitated the invocation of bystander effects in order for any potential strategy to be convincing. At least in the foreseeable future, clinical advance will come from cooperation with other more established disciplines - such as chemotherapy, radiotherapy and immunotherapy. This is inevitable - and necessary - in order to prove that gene therapy can have efficacy as part of a combinatorial therapy, before hoping to move clinical mountains alone. In addition, there will have to be a thorough understanding of the clinical situations in which gene therapy will be used in order both to understand its own limitations, and to exploit its full potential. This will enable it to find the appropriate clinical niche in which its abilities will be optimally useful. Finally, anyone wishing to practise clinical cancer gene therapy will rapidly have to learn the ways of the free market and be able to juggle commercial necessities with ideological purity.

KW - Cancer

KW - Gene therapy immunotherapy

KW - Targeting

KW - Viral vector

UR - http://www.scopus.com/inward/record.url?scp=0033959447&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033959447&partnerID=8YFLogxK

M3 - Article

VL - 7

SP - 2

EP - 8

JO - Gene Therapy

JF - Gene Therapy

SN - 0969-7128

IS - 1

ER -